Cocrystal Pharma, Inc. COCP
Cocrystal Pharma, Inc. (Nasdaq: COCP) is an infectious disease drug developer. Its lead program, CDI-988, is in Phase 1 for Norovirus (prevention and treatment). Its next catalyst on record is CDI-988: Cocrystal expects preliminary efficacy results from CDI-988 Phase 1b study in late 2026 or early 2027. (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: CDI-988 — Cocrystal expects preliminary efficacy results from CDI-988 Phase 1b study in late 2026 or early 2027. (H2 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CC-42344 | Influenza A | small molecule | Phase 2 |
| CDI-988 | Norovirus | small molecule | Phase 1 |
| CC-31244 | HCV | small molecule | Pre-clinical |
Recent results and decisions
- Sep 9, 2026completed enrollment Cocrystal Pharma dosed the last subject in its Phase 1b norovirus challenge study evaluating CDI-988 for prevention and treatment, with no serious adverse events reported.
Completion of this critical milestone brings us closer to addressing one of the most pressing unmet needs in infectious disease.
Filing - Sep 9, 2026completed enrollment Cocrystal announces last subject dosed in Phase 1b norovirus challenge study evaluating CDI-988.
No serious adverse events reported to date
Filing - Apr 30, 2026positive ICAR oral presentation of previously reported Phase 1 data: CDI-988 generally safe and well tolerated up to 1,200 mg, no SAEs, headache most common AE.
CDI-988 was generally safe and well tolerated across doses up to 1,200 mg, with headache as the most common treatment-emergent adverse event and no serious adverse events reported.
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.